Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer.
Yong Gu LeePuneeth GuruprasadGuido GhilardiRaymone PajarilloChristopher Tor SauterRuchi P PatelHatcher J BallardSeok Jae HongInkook ChunNicholas YangKimberly V AmelsbergKatherine D CumminsJakub SvobodaSaar I GillElise A ChongKhrystyna NorthSarah E ChurchJoseph A FraiettaWan-Jung ChangSimon F LaceyXueqing Maggie LuYunlin ZhangKanupriya WhigDavid C. SchultzSara CherryJames GersonStephen J SchusterPatrizia PorazziMarco RuellaPublished in: Cancer discovery (2022)
This study highlights the role of BCL-2 in resistance to CART immunotherapy for cancer and introduces a novel concept for combination therapies-the engineering of CART cells to make them resistant to proapoptotic small molecules, thereby enhancing the therapeutic index of these combination therapies. This article is highlighted in the In This Issue feature, p. 2221.